AbbVie Inc. ABBV reported third-quarter 2025 adjusted EPS of $1.86, which beat the Zacks Consensus Estimate of $1.77. The reported determine additionally exceeded the corporate’s steerage of $1.74-$1.78 issued earlier this month. Earnings declined 38.0% 12 months over 12 months, primarily as a result of greater IPR&D prices incurred throughout the quarter.
ABBV’s revenues of $15.78 billion beat the Zacks Consensus Estimate of $15.59 billion. Gross sales rose 9.1% 12 months over 12 months on a reported foundation and eight.4% on an operational foundation. This reported determine additionally surpassed the corporate’s forecast of $15.5 billion.
Revenues within the quarter have been pushed by strong gross sales of key medicine Rinvoq, Skyrizi, Venclexta and Vraylar, coupled with important contributions from newer medicine, particularly Ubrelvy, Qulipta, Elahere and Vyalev. Gross sales of Humira and Imbruvica declined 12 months over 12 months.
All development charges talked about under are on a year-on-year foundation and at fixed trade charges (CER).
Immunology Medicine Drive ABBV’s High Line
In immunology, internet revenues from Rinvoq for the quarter totaled $2.18 billion, up 34.1%. The upside was doubtless pushed by market share beneficial properties throughout all accepted indications, in addition to the current label growth in big cell arteritis throughout the US and EU in April. Rinvoq’s gross sales beat the Zacks Consensus Estimate and our mannequin estimate, each pegged at $2.16 billion.
Internet revenues recorded from Skyrizi have been $4.71 billion, up 46.0%. This surge in gross sales was doubtless pushed by robust quantity development and continued market share beneficial properties. Skyrizi gross sales beat each the Zacks Consensus Estimate of $4.56 billion and our mannequin estimate of $4.54 billion.
AbbVie’s flagship product Humira recorded a gross sales decline of 55.7% to $993 million for the third quarter. Gross sales in the US declined 65% to $619 million, whereas ex-U.S. market gross sales have been down 20.5% to $374 million. The drug’s general gross sales missed the Zacks Consensus Estimate of $1.15 billion and our mannequin estimate of $1.16 billion.
This substantial decline in Humira gross sales was because of the drug’s lack of exclusivity in the US since January 2023. The drug misplaced its exclusivity in ex-U.S. territories following the launch of generics in 2018.
ABBV Neuroscience Medicine’ Efficiency
Gross sales from the neuroscience portfolio elevated 19.6% to $2.84 billion, pushed by greater gross sales of Botox Therapeutic, melancholy drug Vraylar, and migraine medicine Ubrelvy and Qulipta. Neuroscience gross sales beat the Zacks Consensus Estimate and our mannequin estimate of $2.74 billion and $2.73 billion, respectively.
Whereas Botox Therapeutic gross sales rose 15.8% to $985 million, gross sales of Vraylar elevated 6.7% to $934 million.
Gross sales of Ubrelvy totaled $354 million, up 31.5%. Qulipta gross sales elevated 63.1% to $288 million.
Gross sales of Vyalev, the just lately accepted transformative remedy for superior Parkinson’s illness, totaled $138 million in contrast with $98 million within the earlier quarter.
ABBV Oncology Medicine’ Efficiency
Gross sales from the oncology franchise fell 1.3% to $1.68 billion within the quarter. This slight downtick was as a result of declining Imbruvica gross sales, which greater than offset the expansion in gross sales of newer oncology medicine, Epkinly and Elahere, in addition to rising Venclexta gross sales. The metric missed each the Zacks Consensus Estimate and our mannequin estimate of $1.69 billion and $1.71 billion, respectively.
Third-quarter internet revenues from Imbruvica totaled $706 million, down 14.8%. Although this determine beat our mannequin estimate of $703 million, it missed the Zacks Consensus Estimate of $708 million. ABBV markets this drug in partnership with Johnson & Johnson JNJ.
U.S. gross sales of J&J-partnered Imbruvica declined 17.9% to $507 million as a result of rising competitors from novel oral remedies. AbbVie shares worldwide income earned from Imbruvica with J&J. The corporate’s share of revenue from the drug’s worldwide gross sales declined 5.8% to $199 million.
AbbVie’s leukemia drug Venclexta generated revenues of $726 million within the reported quarter, reflecting 4.9% development. The corporate markets Venclexta in collaboration with Roche RHHBY. Whereas gross sales from the Roche-partnered drug beat the Zacks Consensus Estimate of $712 million, it missed our mannequin estimate of $727 million.
Gross sales of the breast most cancers drug, Elahere, rose 22.4% to $170 million. Nonetheless, the metric missed each the Zacks Consensus Estimate of $199 million and our mannequin estimate of $197 million.
Epkinly gross sales, which comprise AbbVie’s share of revenue from U.S. revenues and product revenues from worldwide markets, amounted to $69 million within the quarter in contrast with $70 million within the earlier quarter. The drug is marketed in partnership with Genmab GMAB.
ABBV’s Aesthetics & Different Medicine
AbbVie’s aesthetics portfolio gross sales have been down 4.2% to $1.19 billion, which missed the Zacks Consensus Estimate of $1.27 billion and our mannequin estimate of $1.30 billion. Botox Beauty gross sales fell 5.4% to $637 million. Juvederm gross sales declined 3.2% to $253 million.
Eye care portfolio gross sales declined 4.2% to $509 million. Gross sales of Ozurdex, a key drug within the portfolio, fell 4.0% to $117 million.
ABBV’s Price Dialogue
Adjusted SG&A bills rose 2.6% 12 months over 12 months to $3.41 billion. Adjusted R&D bills amounted to $2.26 billion, up 9.8%.
ABBV Raises 2025 EPS Steerage
AbbVie raised its EPS steerage for the total 12 months. The corporate expects adjusted EPS to be within the vary of $10.61-$10.65, up from the earlier steerage of $10.38-$10.58.
Our Tackle ABBV’s Outcomes
AbbVie posted better-than-expected Q3 outcomes and likewise raised its EPS steerage for 2025, doubtless pushed by stronger-than-expected gross sales of its newer immunology medicine, Rinvoq and Skyrizi. The corporate’s high line additionally benefited from stable development within the neuroscience franchise, supported by newer belongings like Ubrelvy, Qulipta and Vyalev. Nonetheless, general development was partially offset by Humira’s continued generic erosion and weaker aesthetics gross sales.
Shares of AbbVie have been buying and selling decrease in pre-market in the present day, doubtless because of the softer gross sales efficiency of its aesthetics portfolio, which fell in need of expectations. We had beforehand anticipated the corporate to make a restoration on this section, however gross sales as a substitute declined as demand for facial injectables remained muted.
12 months so far, the inventory has gained 28% in contrast with the trade’s 3% development.
Picture Supply: Zacks Funding Analysis
To offset the declines from its legacy merchandise, AbbVie is strengthening its long-term development platform by means of M&A exercise and inside innovation. In Might, AbbVie secured approval for Emrelis, its first internally developed stable tumor remedy, marking a key milestone in its oncology growth.
Final month, AbbVie submitted two regulatory filings with the FDA — one for pivekimab sunirine (PVEK) to deal with a uncommon and aggressive blood most cancers known as blastic plasmacytoid dendritic cell neoplasm (BPDCN) and one other for tavapadon in early Parkinson’s illness. Each of those medicine have been added by means of prior acquisitions, and along with Emrelis, they replicate AbbVie’s accelerating give attention to increasing its oncology and neuroscience footprint. The corporate has accomplished greater than 30 M&A transactions for the reason that starting of 2024, underscoring its proactive method to pipeline diversification and portfolio renewal geared toward driving sustainable long-term development.
AbbVie Inc. Worth
AbbVie Inc. value | AbbVie Inc. Quote
ABBV’s Zacks Rank
AbbVie presently carries a Zacks Rank #3 (Maintain). You may see the entire checklist of in the present day’s Zacks #1 Rank (Sturdy Purchase) shares right here.
Roche Holding AG (RHHBY) : Free Inventory Evaluation Report
Johnson & Johnson (JNJ) : Free Inventory Evaluation Report
AbbVie Inc. (ABBV) : Free Inventory Evaluation Report
Genmab A/S Sponsored ADR (GMAB) : Free Inventory Evaluation Report
This text initially printed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
